Ustekinumab

When she was diagnosed with Crohn’s disease in 2017, Shanna Quinn couldn’t believe it. “I knew other people with Crohn’s or colitis , and my perception was that they were always in the bathroom, malnourished or couldn’t eat anything — that wasn’t me,” said Quinn, who was in her mid-30s at the time and otherwise healthy and active. Crohn’s, a form of inflammatory bowel disease (IBD) that affects the digestive tract, doesn’t look the same for everyone, and its main cause is unknown. Typical symptoms may include diarrhea, bloating, constipation and rectal bleeding. Faced with a nagging pain in her abdomen, Quinn saw a doctor who was dismissive, suggesting she lose weight. But the pain continued, and she would get sick for extended periods after eating something healthy, such as popcorn or a salad. She pressed her primary care doctor to order a CT scan, which revealed inflammation in her small intestine, leading to a colonoscopy and a Crohn’s diagnosis. Second opinion for Crohn’s disease Frustrated with the care she received elsewhere, Quinn wanted a second opinion — and a doctor who made her feel comfortable and heard. In early 2019, she saw Sushila Dalal, MD , a gastroenterologist at UChicago Medicine’s IBD Center, and her anxieties were eased. “My old GI doctor hadn’t really explained anything, and I still didn’t fully believe I had Crohn’s,” Quinn said. “When I met Dr. Dalal, she could tell I was overwhelmed. She took the time to go through my scans and explain why my Crohn’s symptoms looked different from others.” Dalal explained that Quinn had a stricture, or a narrowing in her intestine, causing a partial blockage. She had a healthy colon, but the end of the small intestine narrowed to the size of a pinhole, which could cause food to back up and her upper bowel to stretch like a balloon. “Crohn’s is an overactivation of the immune system,” Dalal said. “It can happen in any part of the intestinal tract — from the mouth to the anus — though we often see it at the end of the small intestine and the beginning of the colon, which was the case with Shanna.” This helped Quinn understand why she was having IBD symptoms such as pain, bloating and occasional vomiting , rather than frequent diarrhea like some other people she knew with IBD. Finding the right IBD treatment When Quinn first met with Dalal, she was nervous about her treatment options. After a long discussion, the two decided she could hold off on medication for the time being and schedule a low-risk intestinal surgery for December 2019. The procedure, called an ileocecectomy, involves removing a small part of the bowel. At the same time, Quinn found out she needed surgery for uterine fibroids. That prompted UChicago Medicine GI surgeon Benjamin Shogan, MD , and gynecologic surgeon Laura Douglass, MD , to team up and perform both procedures during the same surgical appointment. In early 2020, following the successful surgery, Quinn and Dalal revisited the idea of using biologic medications to help manage her Crohn’s. It is a chronic disease, so patients generally require medication for life. “It’s funny to think about where my brain was then versus where it is now,” said Quinn. “I was extremely nervous about going on a medication. Getting over the hump of — this is something you’re likely going to have to do for a lifetime — is really, really weird.” Quinn agreed to start taking ustekinumab, a monoclonal antibody targeting two proteins in the body that can cause inflammation. Team approach targets different symptoms, needs Just as IBD symptoms vary by patient, so do their treatment plans. After years of being symptom-free while on her medication, Quinn had a flareup of pain, constipation and bloating in 2024. It was time to reevaluate. Dalal temporarily put Quinn on a steroid to ease the new symptoms. After a thorough round of scans, testing and more discussions, Dalal and Quinn opted for another biologic medication, adalimumab, which targets a different part of the immune system. Like many other IBD patients who have to navigate changing insurance coverage, she eventually transitioned to a biosimilar version of adalimumab. So far, the treatment has been a success. Beyond praising Dalal’s guidance and bedside manner, Quinn also credits UChicago Medicine’s expansive IBD team that includes nurses, dietitians, a psychologist, a support group and more. “Shanna is an inspiration and really exemplifies what it means to advocate for yourself in your medical care,” said Anna Gomberg, Executive Director of UChicago Medicine’s IBD Center and leader of the IBD support group. “I’m so glad she’s part of our support group. She’s part of the team, too!” The highly personalized care is by design. “It’s very common for my patients to have this idea that IBD looks the same for all IBD patients,” Dalal said. “But just because one person’s symptoms are different than another’s, it doesn’t make either case more valid than the other.” Quinn, now 43, is doing well. The resident of Chicago's Uptown neighborhood is an avid weightlifter, regularly practices meditation and has returned to the office for her job in social media management. “Something I’m really thankful for, with Dr. Dalal, is that it feels like we’re in this together,” Quinn said. “She built a lot of trust with me.” Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Shares in Protagonist Therapeutics soared more than 30% on Friday after the Wall Street Journal reported that it may soon be bought by Johnson & Johnson. The biotech's valuation had hovered near $4.2 billion at market close on Thursday, before takeout rumours emerged.The pair are co-developing icotrokinra, an oral IL-23 inhibitor poised to be a major growth driver for J&J's inflammation and immunology (I&I) portfolio (see – ViewPoints: AAD25 – J&J leadership tells how icotrokinra is upping the ante across the board in psoriasis).The pharma has already filed for US approval in psoriasis, fuelled by Phase III data suggesting icotrokinra has best-in-disease efficacy for a once-daily oral therapeutic; the candidate also bested Bristol Myers Squibb's oral TYK2 inhibitor Sotyktu (deucravacitinib) in a head-to-head study (see – Spotlight On: J&J's icotrokinra goes from promise to proof, cementing its case in psoriasis and Physician Views Results: Poll shows US dermatologists see icotrokinra as a differentiated oral option in psoriasis).Outside of psoriasis, J&J is pursuing a broad I&I strategy for the IL-23 blocker. Later this month, J&J is planning to launch the Phase III ICONIC-UC trial in patients with ulcerative colitis, and the Phase IIb/III ICONIC-CD study in Crohn's disease.With profits from J&J's former I&I headliner, Stelara (ustekinumab) falling fast following the entrance of biosimilar competition, icotrokinra could help bolster the pharma's bottom line (see – Vital Signs: J&J makes the best of Stelara's successful sink). Icotrokinra wouldn't be the only asset J&J gains from a Protagonist purchase, however; the biotech is also partnered with Takeda on rusfertide, an investigational hepcidin mimetic in Phase III testing for polycythemia vera. Top-line results presented at this year's American Society of Clinical Oncology (ASCO) meeting showed that 76.9% of patients responded to rusfertide treatment during weeks 20-32, versus 32.9% on placebo.If the acquisition goes through, it will be J&J's second major takeout this year. The pharma agreed in January to buy neurology firm Intra-Cellular for $14.6 billion, gaining oral schizophrenia and bipolar depression therapy Caplyta (lumateperone).